Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $1.80 Million Position in Moderna, Inc. (NASDAQ:MRNA)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 6.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 18,111 shares of the company’s stock after selling 1,227 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Moderna were worth $1,801,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of MRNA. The Manufacturers Life Insurance Company boosted its position in Moderna by 77.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after acquiring an additional 1,690,341 shares during the last quarter. Invesco Ltd. grew its stake in Moderna by 19.8% in the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after purchasing an additional 517,683 shares in the last quarter. Wellington Management Group LLP increased its holdings in Moderna by 9.3% during the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock worth $579,572,000 after buying an additional 476,201 shares during the last quarter. Bamco Inc. NY increased its position in Moderna by 4,863.6% during the third quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock worth $44,091,000 after buying an additional 418,269 shares during the last quarter. Finally, abrdn plc lifted its stake in shares of Moderna by 477.5% during the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock worth $48,091,000 after buying an additional 399,843 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Insider Activity at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the completion of the sale, the director now owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total value of $1,663,800.00. Following the transaction, the director now owns 2,026,931 shares in the company, valued at $224,827,186.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 647 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 139,954 shares of company stock valued at $14,822,576. Insiders own 15.20% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the subject of several research reports. Oppenheimer raised their price objective on shares of Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 price objective on shares of Moderna in a report on Tuesday, April 9th. HSBC reissued a “reduce” rating and set a $86.00 target price (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. UBS Group upped their price target on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday, May 2nd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average target price of $126.89.

Moderna Trading Up 0.5 %

Shares of Moderna stock traded up $0.64 on Wednesday, hitting $121.71. The stock had a trading volume of 709,486 shares, compared to its average volume of 4,089,359. The stock has a 50 day moving average of $106.10 and a 200 day moving average of $95.05. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $142.79. The firm has a market capitalization of $46.64 billion, a P/E ratio of -7.73 and a beta of 1.57.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $0.52. The firm had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company’s revenue was down 91.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.19 earnings per share. Sell-side analysts expect that Moderna, Inc. will post -7.47 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.